The Price to book ratio is the current stock price of a firm divided by the book value per share. The Price to Book ratio for BioLargo, Inc. OTCPK:BLGO is -29.305189. A lower price to book ratio signals that the stock might be undervalued. Similarly, Price to cash flow ratio is another useful ratio in determining a firm’s value. The Price to Cash Flow for BioLargo, Inc. (OTCPK:BLGO) is -7.770522. This ratio is determined by dividing the market value of a firm by cash from operating activities. Additionally, the price to earnings ratio is another crowd-pleasing way for analysts and investors to think through a firm’s profitability. The price to earnings ratio for BioLargo, Inc. (OTCPK:BLGO) is -3.222748. This ratio is found by taking the current stock price and dividing by EPS.
Following all the swirling information about publically traded companies can be quite a task. Every day there may be new pieces of news that emerge about a specific firm. The prudent investor is typically able to keep abreast of the information, but most importantly think through what news is worth paying attention to, and what news should be filtered out. Keeping a smart eye on earnings reports and fundamental firm data can play a big part in picking the right stocks for the portfolio. Once the numbers have been crunched, investors should be able to see things a little bit simpler and know what the general feel for the stock is. Of period there will be stocks that look good after thorough examination but still fail to perform as expected.
Checking in on some valuation rankings, BioLargo, Inc. (OTCPK:BLGO) has a Value Composite score of 97. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a firm with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued firm. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is right now sitting at 98.
BioLargo, Inc. (OTCPK:BLGO) has a current MF Rank of 18186. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to detect high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks.
Further, we can see that BioLargo, Inc. (OTCPK:BLGO) has a Shareholder Yield of -0.23338 and a Shareholder Yield (Mebane Faber) of -0.33454. The first value is determined by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the company is giving back to shareholders via a few alternate avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.
The Piotroski F-Score is a scoring system between 1-9 that determines a company’s financial strength. The score helps think through if a firm’s stock is valuable or not. The Piotroski F-Score of BioLargo, Inc. (OTCPK:BLGO) is 4. A score of nine signals a high value stock, while a score of one signals a low value stock. The score is determined by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings. It is also determined by a change in gearing or leverage, liquidity, and change in shares in issue. The score is also calculated by change in gross margin and change in asset turnover.
Investors may be interested in studying the Gross Margin score on shares of BioLargo, Inc. (OTCPK:BLGO). The name right now has a score of 44. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative.
Volatility/PI
Stock volatility is a percentage that signals whether a stock is a desirable purchase. Investors look at the Volatility 12m to think through if a firm has a low volatility percentage or not over the period of a year. The Volatility 12m of BioLargo, Inc. (OTCPK:BLGO) is 63.6712. This is determined by taking weekly log normal returns and standard deviation of the stock price over one year annualized. The lower the number, a firm is thought to have low volatility. The Volatility 3m is a similar percentage calculated by the daily log normal returns and standard deviation of the stock price over 3 months. The Volatility 3m of BioLargo, Inc. (OTCPK:BLGO) is 74.7594. The Volatility 6m is the same, except measured over the period of six months. The Volatility 6m is 86.5753.
The Price Index is a ratio that signals the return of a stock price over a past timeframe. The price index of BioLargo, Inc. (OTCPK:BLGO) for last month was 0.82097. This is determined by taking the current stock price and dividing by the stock price one month ago. If the ratio is greater than 1, then that means there has been an accelerate in price over the month. If the ratio is less than 1, then we can think through that there has been a decrease in price. Similarly, investors look up the stock price over 12 month periods. The Price Index 12m for BioLargo, Inc. (OTCPK:BLGO) is 0.54091.
There are many alternate tools to think through whether a firm is profitable or not. One of the most crowd-pleasing ratios is the “Return on Assets” (aka ROA). This score signals how profitable a firm is relative to its total assets. The Return on Assets for BioLargo, Inc. (OTCPK:BLGO) is -16.079316. This number is determined by dividing net income after tax by the firm’s total assets. A firm that manages their assets well will have a higher return, while a firm that manages their assets poorly will have a lower return.
Investors who are able to wipe the slate clean and take a fresh look at a certain stock may be able to make more informed decisions that will hopefully lead to increased profits in the long-term. Figuring out when to sell an underperforming stock may end up being just as paramount as figuring out which stocks to buy. As the share market continues to trade near record levels, investors will be closely following trading action heading into the latter half of the year. With many stocks reaching new highs, investors may have to make sure that they aren’t getting too overconfident with trades. When a few winning trades are strung together, investors may feel like they have the Midas touch and they can do no wrong. Nobody knows for sure how long stocks will remain in favor with investors. Keeping track of the portfolio’s contents can aid when quick decisions have to be made. There may come a time when the tide turns and making a winning trade may seem impossible. Investors might want to have a plan in place in case of a sudden major market downturn. Keeping the portfolio stable during periods of market exposure may aid prepare for unforeseen events in the future. Although there are many market enthusiasts that think the bull run may be on its last legs, there are just as many who believe that the best is yet to come, and there is much mor e room for stocks to climb.
The Price to Book ratio for Anixa Biosciences, Inc. NasdaqCM:ANIX is 11.939998. The Price to book ratio is the current stock price of a firm divided by the book value per share. A lower price to book ratio signals that the stock might be undervalued. Similarly, Price to cash flow ratio is another useful ratio in determining a firm’s value. The Price to Cash Flow for Anixa Biosciences, Inc. (NasdaqCM:ANIX) is -18.920949. This ratio is determined by dividing the market value of a firm by cash from operating activities. Additionally, the price to earnings ratio is another crowd-pleasing way for analysts and investors to think through a firm’s profitability. The price to earnings ratio for Anixa Biosciences, Inc. (NasdaqCM:ANIX) is -7.20798. This ratio is found by taking the current stock price and dividing by EPS.
Diversification can be an paramount aspect of any investor’s portfolio. Investors may single out to spread out stock holdings between foreign stocks and stocks with alternate market capitalizations. Investors may must first hearken of the uncertainty associated with possessing a wide variation of stocks. Owning stocks that belong to alternate industries may also be a aid to the success of the portfolio. Often times, sectors may trade out of kilter being market leaders. Owning all one sector may leave too much uncertainty exposed if the sector swiftly tanks and falls out of favor with investors. Investors may have to sporadically do a strategic analysis of the equity portion of the portfolio. Knowing affirmatively what is held may aid the investor when the time comes to make some alterations.
Volatility/PI
Stock volatility is a percentage that signals whether a stock is a desirable purchase. Investors look at the Volatility 12m to think through if a firm has a low volatility percentage or not over the period of a year. The Volatility 12m of Anixa Biosciences, Inc. (NasdaqCM:ANIX) is 118.6609. This is determined by taking weekly log normal returns and standard deviation of the stock price over one year annualized. The lower the number, a firm is thought to have low volatility. The Volatility 3m is a similar percentage calculated by the daily log normal returns and standard deviation of the stock price over 3 months. The Volatility 3m of Anixa Biosciences, Inc. (NasdaqCM:ANIX) is 113.4499. The Volatility 6m is the same, except measured over the period of six months. The Volatility 6m is 86.5721.
The Price Index is a ratio that signals the return of a stock price over a past timeframe. The price index of Anixa Biosciences, Inc. (NasdaqCM:ANIX) for last month was 0.86882. This is determined by taking the current stock price and dividing by the stock price one month ago. If the ratio is greater than 1, then that means there has been an accelerate in price over the month. If the ratio is less than 1, then we can think through that there has been a decrease in price. Similarly, investors look up the stock price over 12 month periods. The Price Index 12m for Anixa Biosciences, Inc. (NasdaqCM:ANIX) is 1.93301.
Further, we can see that Anixa Biosciences, Inc. (NasdaqCM:ANIX) has a Shareholder Yield of -0.223876 and a Shareholder Yield (Mebane Faber) of -0.1026. The first value is determined by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the company is giving back to shareholders via a few alternate avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.
Checking in on some valuation rankings, Anixa Biosciences, Inc. (NasdaqCM:ANIX) has a Value Composite score of 94. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a firm with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued firm. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is right now sitting at 95.
Anixa Biosciences, Inc. (NasdaqCM:ANIX) has a current MF Rank of 17837. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to detect high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks.
There are many alternate tools to think through whether a firm is profitable or not. One of the most crowd-pleasing ratios is the “Return on Assets” (aka ROA). This score signals how profitable a firm is relative to its total assets. The Return on Assets for Anixa Biosciences, Inc. (NasdaqCM:ANIX) is -1.245276. This number is determined by dividing net income after tax by the firm’s total assets. A firm that manages their assets well will have a higher return, while a firm that manages their assets poorly will have a lower return.
The Piotroski F-Score is a scoring system between 1-9 that determines a company’s financial strength. The score helps think through if a firm’s stock is valuable or not. The Piotroski F-Score of Anixa Biosciences, Inc. (NasdaqCM:ANIX) is 4. A score of nine signals a high value stock, while a score of one signals a low value stock. The score is determined by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings. It is also determined by a change in gearing or leverage, liquidity, and change in shares in issue. The score is also calculated by change in gross margin and change in asset turnover.
Investors may be interested in studying the Gross Margin score on shares of Anixa Biosciences, Inc. (NasdaqCM:ANIX). The name right now has a score of 51. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative.
Investors might be trying to think through the best way to approach the share market. After creating a plan that includes a list of stocks to purchase, investors may be surveying to gauge the best time to enter the trade. With markets still cruising along at high altitudes, investors may be worried about buying at the top. Most individuals would probably agree that getting out before the market drops would be the best play. Obviously this is much clearer said than done. If the warning signs were blatant, everyone would know affirmatively when to sell and when to re-buy. When the share market has a big decline, the natural instinct is generally to sell in order to protect gains or eliminate added losses. Trying to time the market can have negative implications for investors who are not prepared to handle extremely volatile market conditions. Being prepared for any sudden change in the overall economy or share market conditions may aid the investor remain afloat for the long haul.
